Genetic Susceptibility to Radiation Induced Thyroid Cancer (NCT04139096) | Clinical Trial Compass
CompletedNot Applicable
Genetic Susceptibility to Radiation Induced Thyroid Cancer
France60 participantsStarted 2019-09-22
Plain-language summary
Case control on thyroid cancer occuring in a cohort of 7300 subjects treated during their childhood, mostly by radiotherapy, for a skin Angioma at Gustave Roussy, Villejuif France between 1947 and 1973.
This case control study, which is included in a larger european project, aims to investigate the DNA variant interacting with the risk of radiation induced thyroid cancer after irradiation.
The sutdy is planed to include about 30 cases and 30 controls. Matching criteria are date of birth, gender, and age at irradiation.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Diganosis of thyroid cancer during the followup or selected as a control matched on gender, date of birth and age at skin hemangioma diagnosis.
Exclusion Criteria:
No available adress Refusal
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this study focused on genetic susceptibility to radiation-induced thyroid cancer and has already been completed, could you help me find out if the results have been published, and whether any genetic risk factors were identified that might be relevant to my own situation?
2This trial was measuring the number of differentiated thyroid carcinoma cases — does that finding change how you think about monitoring or screening for me, especially if I have a history of radiation exposure?
3Because this was a genetic susceptibility study rather than a treatment trial, does it involve any genetic testing that you think would be worthwhile for me to pursue based on my personal or family history?
4Given that this study looked at how certain genes may increase the risk of developing thyroid cancer after radiation exposure, is there anything in my medical history — like past radiation treatments or imaging — that would make this research particularly relevant to my care?
5Are there any follow-up studies or registries connected to this completed trial that you think would be worth discussing as a next step for understanding my own thyroid cancer risk?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of Differentiated thyroid carcinoma
Timeframe: From hemangioma diagnosis to the end of the followup, in average 45 years after hemangioma diagnosis
Trial details
NCT IDNCT04139096
SponsorInstitut National de la Santé Et de la Recherche Médicale, France